Axovant scraps dementia drug development after negative results
The 5-ht6 antagonist failed to meet its primary efficacy endpoints in the phase 2b HEADWAY and pilot phase 2 Gait and Balance studies. In the HEADWAY trial, intepirdine
Charles River Laboratories International (CRL) has signed definitive agreements to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations in Pennsylvania, US for roughly $470m in cash.
The role of BRUDAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve the TLANDO New Drug Application (“NDA”) is anticipated
This Breakthrough Therapy Designation is supported by positive Phase 2b results previously announced in September 2017,11 and marks 13 Breakthrough Therapy Designations granted to AbbVie's investigational treatments since